Early positive signals of cognitive outcomes in mild to moderate Alzheimer patients treated with the synaptic regenerative small molecule, SPG302
Once-daily treatment with the novel synaptogenic small molecule, SPG302, is safe and well tolerated in AD participants over the course of 28 weeks was associated with early signs of cognitive improvements.
Authors
- Stella T. Sarraf (ORCID: https://orcid.org/0000-0001-8507-6490)
- Valerie Bramah
- Sharron Gargosky
- Aimee Cayzer
- Craig Erickson
- Lauren Priest
- Peter Vanderklish
- Bruce Brew
Institutions
- TiGenix (Spain) (ES)
- Flinders Medical Centre (AU)
- St Vincent's Hospital Melbourne (AU)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_109023
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00